Payment overview · 2025
General Payments
$747.00
36 reported records · 14 companies
Healthcare provider profile · identity verified
David Charles Terrell, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · LAKE CITY, FL · NPI 1811411754
Verified facts
What the public records show
CMS Open Payments records show David Charles Terrell, ARNP received $747.00 in general payments during 2025 across 36 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 268 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 203 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $182.11 | 24.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $148.94 | 19.9% | 13 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $79.64 | 10.7% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $47.94 | 6.4% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $46.98 | 6.3% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $46.17 | 6.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.68 | 5.8% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.27 | 4.9% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $30.74 | 4.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.07 | 2.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.24 | 2.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.35 | 2.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.01 | 2.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.86 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $747.00 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $182.11 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $182.11 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $152.90 | 13 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $79.64 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $47.94 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $46.98 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $46.17 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $36.27 | 2 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $30.74 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $26.58 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 77 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 268 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
61 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
77 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
77 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
268 | 53 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
203 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 668 | 152 |
| Amlodipine Besylate | Amlodipine Besylate | 482 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 384 | 94 |
| Lisinopril | Lisinopril | 361 | 97 |
| Gabapentin | Gabapentin | 343 | 94 |
| Ozempic | Semaglutide | 268 | 53 |
| Furosemide | Furosemide | 267 | 72 |
| Alprazolam | Alprazolam | 265 | 39 |
| Omeprazole | Omeprazole | 263 | 65 |
| Tramadol Hcl | Tramadol Hcl | 251 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 241 | 66 |
| Zolpidem Tartrate | Zolpidem Tartrate | 211 | 37 |
| Eliquis | Apixaban | 203 | 36 |
| Potassium Chloride | Potassium Chloride | 197 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 193 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 192 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 192 | 57 |
| Lorazepam | Lorazepam | 184 | 43 |
| Losartan Potassium | Losartan Potassium | 184 | 56 |
| Trazodone Hcl | Trazodone Hcl | 176 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 171 | 43 |
| Metformin Hcl | Metformin Hcl | 164 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 153 | 36 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 135 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 135 | 41 |
| Carvedilol | Carvedilol | 129 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 124 | 52 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 120 | 46 |
| Methylprednisolone | Methylprednisolone | 113 | 82 |
| Famotidine | Famotidine | 112 | 32 |
| Meloxicam | Meloxicam | 104 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 97 | 40 |
| Fluoxetine Hcl | Fluoxetine Hcl | 93 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 26 |
| Montelukast Sodium | Montelukast Sodium | 92 | 29 |
| Simvastatin | Simvastatin | 91 | 21 |
| Donepezil Hcl | Donepezil Hcl | 90 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 27 |
| Sertraline Hcl | Sertraline Hcl | 87 | 23 |
| Azithromycin | Azithromycin | 86 | 65 |
| Tizanidine Hcl | Tizanidine Hcl | 83 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 80 | 42 |
| Ropinirole Hcl | Ropinirole Hcl | 80 | 17 |
| Pregabalin | Pregabalin | 79 | 17 |
| Jardiance | Empagliflozin | 77 | 21 |
| Memantine Hcl | Memantine Hcl | 74 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 14 |
| Ezetimibe | Ezetimibe | 66 | 21 |
| Lactulose | Lactulose | 66 | 22 |
| Bupropion Xl | Bupropion Hcl | 62 | 21 |
| Farxiga | Dapagliflozin Propanediol | 61 | 16 |
| Metformin Hcl Er | Metformin Hcl | 61 | 16 |
| Myrbetriq | Mirabegron | 61 | suppressed |
| Prednisone | Prednisone | 61 | 39 |
| Valsartan | Valsartan | 59 | 13 |
| Clonazepam | Clonazepam | 58 | suppressed |
| Spironolactone | Spironolactone | 57 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 56 | 16 |
| Allopurinol | Allopurinol | 55 | 14 |
| Mirtazapine | Mirtazapine | 54 | 13 |
| Trulicity | Dulaglutide | 52 | suppressed |
| Temazepam | Temazepam | 49 | suppressed |
| Nystatin | Nystatin | 48 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | 12 |
| Topiramate | Topiramate | 48 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | suppressed |
| Glipizide | Glipizide | 46 | 11 |
| Januvia | Sitagliptin Phosphate | 46 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 20 |
| Cephalexin | Cephalexin | 45 | 37 |
| Meclizine Hcl | Meclizine Hcl | 43 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 42 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | 17 |
| Levofloxacin | Levofloxacin | 41 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 41 | suppressed |
| Baclofen | Baclofen | 40 | suppressed |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Linzess | Linaclotide | 40 | suppressed |
| Methocarbamol | Methocarbamol | 40 | 12 |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Primidone | Primidone | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | 23 |
| Finasteride | Finasteride | 35 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 34 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 29 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Celecoxib | Celecoxib | 32 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Glimepiride | Glimepiride | 31 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 15 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 22 |
| Fluconazole | Fluconazole | 27 | 16 |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 23 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 20 |
| Benztropine Mesylate | Benztropine Mesylate | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 16 |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | 12 |
| Phenobarbital | Phenobarbital | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Constulose | Lactulose | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Leflunomide | Leflunomide | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Ursodiol | Ursodiol | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 11 | 11 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $747.00 · 36 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, Dexcom G6 Transmitter, JARDIANCE, JOT DX, Kerendia, Korlym, MOUNJARO, NURTEC ODT, Ozempic, REXULTI, Rybelsus, Sunosi, VOQUEZNA, XIFAXAN, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error